Free Trial

FSD Pharma Q3 2023 Earnings Report

FSD Pharma EPS Results

Actual EPS
-$0.03
Consensus EPS
-$0.14
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

FSD Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

FSD Pharma Announcement Details

Quarter
Q3 2023
Time
After Market Closes

Conference Call Resources

Grab these five dividend cheat sheets (Ad)

Would you like a simple set of guidelines for building a rock solid dividend portfolio? Including the two specific tickers I just put $50k into? Well, it’s all included in these FIVE Dividend Cheat Sheets

>> You can grab your FREE, laminated copies right here << 

FSD Pharma Earnings Headlines

Boost Your 2025 Income with Just $30
Are you ready to start 2025 with a steady income stream from stocks priced under $30? Our latest guide introduces you to straightforward and effective options strategies tailored for everyday investors in 2025. With clear, step-by-step insights, you’ll discover how to turn well-known companies like Ford and Intel into reliable sources of monthly income. No complicated charts. No Wall Street jargon. Just actionable strategies that work in the current market landscape.
See More FSD Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like FSD Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FSD Pharma and other key companies, straight to your email.

About FSD Pharma

FSD Pharma (NASDAQ:HUGE), a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. FSD Pharma Inc. is headquartered in Toronto, Canada.

View FSD Pharma Profile

More Earnings Resources from MarketBeat